Phase 1 Unresectable Solid Tumor Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting
Phase 1
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
CholangiocarcinomaAdvanced Solid TumorMetastatic Solid Tumor+1 more
Massachusetts General Hospital70 enrolled1 locationNCT06302621
Recruiting
Phase 1Phase 2
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Metastatic CancerSolid TumorUnresectable Solid Tumor+3 more
Spago Nanomedical AB90 enrolled2 locationsNCT06184035
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Metastatic Solid TumorAdvanced Unresectable Solid Tumor
TopAlliance Biosciences499 enrolled24 locationsNCT04137900